| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
64,210,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
141 |
Avg
Vol: |
1,513,129 |
| 52
Week Range: |
$0.000001 - $0.238 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
410,196 |
425,190 |
| Total Sell Value |
$0 |
$0 |
$28,714 |
$38,646 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Perkins Adelene Q |
Pres & Chief Business Officer |
• – – |
2008-12-16 |
4 |
B |
$7.41 |
$5,188 |
D/D |
700 |
233,038 |
2.74 |
- |
|
| Perkins Adelene Q |
Pres & Chief Business Officer |
• – – |
2008-11-25 |
4 |
B |
$5.70 |
$570 |
D/D |
100 |
232,338 |
2.66 |
- |
|
| Perkins Adelene Q |
Pres & Chief Business Officer |
• – – |
2008-11-24 |
4 |
B |
$5.87 |
$135,224 |
D/D |
21,941 |
232,238 |
2.74 |
- |
|
| Beacon Co |
10% Owner |
– – • |
2008-11-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000,000 |
|
- |
|
| Rosebay Medical Co L.p. |
10% Owner |
– – • |
2008-11-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000,000 |
|
- |
|
| Adams Julian |
President, R&D & CSO |
• – – |
2008-10-28 |
4 |
OE |
$2.04 |
$320,583 |
D/D |
137,413 |
262,943 |
|
- |
|
| Holtzman Steven H |
Chief Executive Officer |
• • – |
2008-10-27 |
4/A |
OE |
$3.48 |
$115,376 |
D/D |
33,154 |
345,668 |
|
- |
|
| Holtzman Steven H |
CEO |
• • – |
2008-10-27 |
4 |
OE |
$2.04 |
$229,252 |
D/D |
88,742 |
401,256 |
|
- |
|
| Holtzman Steven H |
President and CEO |
• • – |
2008-08-27 |
4 |
B |
$7.40 |
$163,562 |
D/D |
22,103 |
256,926 |
2.81 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2008-03-17 |
4 |
B |
$5.90 |
$4,583 |
D/D |
776 |
210,297 |
2.66 |
- |
|
| Holtzman Steven H |
Chairman and CEO |
• • – |
2007-09-14 |
4 |
B |
$9.12 |
$45,601 |
D/D |
5,000 |
234,823 |
2.81 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-06-15 |
4 |
B |
$10.63 |
$106,395 |
D/D |
10,000 |
209,521 |
2.74 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-11 |
4 |
B |
$10.79 |
$32,020 |
D/D |
2,946 |
199,521 |
2.74 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-10 |
4 |
B |
$10.79 |
$27,008 |
D/D |
2,500 |
196,575 |
2.74 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-09 |
4 |
B |
$10.95 |
$10,950 |
D/D |
1,000 |
194,075 |
2.74 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-07 |
4/A |
B |
$10.88 |
$43,560 |
D/D |
4,000 |
193,075 |
2.74 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-07 |
4 |
S |
$10.88 |
$43,560 |
D/D |
(4,000) |
193,075 |
|
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-04 |
4/A |
B |
$10.99 |
$113,456 |
D/D |
10,248 |
189,075 |
2.74 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-04 |
4 |
S |
$10.99 |
$22,771 |
D/D |
(2,048) |
189,075 |
|
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-04 |
4 |
B |
$11.00 |
$90,685 |
D/D |
8,200 |
187,027 |
2.74 |
- |
|
| Perkins Adelene Q |
EVP and Chief Business Officer |
• – – |
2007-05-03 |
4 |
B |
$11.24 |
$10,118 |
D/D |
900 |
178,827 |
2.74 |
- |
|
| Levine Arnold J |
Director |
– • – |
2007-03-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,500 |
15,287 |
|
- |
|
| Prospect Management Co Llc |
10% Owner |
– – • |
2006-09-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,102,398 |
|
- |
|
| Schnell David |
10% Owner |
– – • |
2006-09-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,102,398 |
|
- |
|
| Barkas Alexander E |
10% Owner |
– – • |
2006-09-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,102,398 |
|
- |
|
227 Records found
|
|
Page 7 of 10 |
|
|
